Amarin Corporation plc
AMRNHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Amarin Corporation plc focuses on Drug Manufacturers - General services and products. Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and. At a $303.8M market cap, Amarin Corporation plc ranks as a small-cap company within healthcare. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Market Cap
$303.8M
Beta
0.82
P/E (TTM)
—
P/E (Fwd)
14.79
EPS (TTM)
$-1.60
EPS (Fwd)
$0.98
ROE
-7.3%
ROA
-0.5%
Cash
$307.8M
Total Debt
$7.7M
Free CF
$2.2M
52W Change
23.4%
Annual Financials
Cash vs Debt
Amarin Corporation plc holds $307.8M in cash against $7.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $2.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -7.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $583.2M (2021) to $213.6M (2025), a 63% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AMRN.